Key result
Early evolocumab post-ACS yields ~2-fold higher 1-year LDL-C goal attainment vs conventional care.
Why the study?
Real-world studies continue to show poor LDL-C goal attainment after ACS, and the AMUNDSEN trial has renewed interest in the optimal timing of PCSK9 inhibition and which patients may benefit most from upfront initiation.
Does very early or upfront initiation of PCSK9 inhibition improve LDL-C goal attainment and reduce recurrent cardiovascular events compared to conventional delayed care in patients surviving an acute coronary syndrome?
Does very early or upfront initiation of PCSK9 inhibition improve LDL-C goal attainment and reduce recurrent cardiovascular events compared to conventional delayed care in patients surviving an acute coronary syndrome?
This review highlights that following the AMUNDSEN trial, very early initiation of evolocumab after ACS more than doubles 1-year LDL-C goal attainment (82% vs. 40%) compared to guideline-directed delayed intensification, supporting the consideration of upfront PCSK9 inhibition to maximize both the magnitude and duration of LDL-C lowering.
Answers are grounded in this paper and cite their sources.
Early evolocumab post-ACS may improve LDL-C attainment; extends registry data on timing but leaves event reduction open.
Patients surviving an acute coronary syndrome (ACS) remain at substantial risk of recurrent cardiovascular events, particularly during the first months after the index event. Current European recommendations support immediate oral high intensity lipid lowering therapy, targeting an LDL-C level <55 mg/dL (<1.4 mmol/L) together with a ≥50% reduction from baseline. More recently, the therapeutic approach has shifted towards earlier treatment intensification with ezetimibe during the index hospitalization. Nevertheless, real-world studies such as DA VINCI and SANTORINI continue to show poor LDL-C goal attainment and limited use of combination lipid-lowering therapy.Recent data from the SWEDEHEART registry further suggest that delayed treatment intensification and late achievement of lipid targets may translate into avoidable residual cardiovascular risk. The AMUNDSEN trial has renewed interest in the optimal timing of PCSK9 inhibition after ACS. Very early initiation of evolocumab resulted in markedly higher LDL-C goal attainment at 1 year compared with conventional care which included the possible selective and delayed use of PCSK9 inhibitors, as recommended in the guidelines (82% vs. 40%). In a disctinct objective, the possibility that early pleiotropic (non-LDL) effects of evolocumab could improve short-term clinical outcome was not confirmed at 1-year followup.These findings raise an important question: should the benefit of lipid-lowering therapy be assessed only according to the LDL-C level achieved at a given time point, or should the duration of exposure to lower LDL-C also be considered? Evidence from randomized trials, meta-analyses, and long-term follow-up studies supports the concept that both the magnitude and duration of LDL-C reduction contribute to cardiovascular benefit. This review discusses the implications of AMUNDSEN in the context of contemporary evidence and examines which patients may derive the greatest benefit from upfront PCSK9 inhibition, considering both recurrent clinical risk and the magnitude of LDL-C reduction required to achieve recommended targets.
No takes yet. Share an insight, caveat, or question.
Sabouret et al. (2026) conducted a review in Acute coronary syndrome. Upfront PCSK9 inhibition (evolocumab) vs. Conventional care with possible selective and delayed use of PCSK9 inhibitors was evaluated on LDL-C goal attainment at 1 year (reported from the AMUNDSEN trial). Very early initiation of evolocumab after ACS achieved markedly higher 1-year LDL-C goal attainment than conventional care in the AMUNDSEN trial.
Synapse has enriched 10 related papers. Consider them for comparative context: